Atrial Fibrillation in Heart Failure Patients with Preserved or Reduced Ejection Fraction. Prognostic significance of Rhythm control strategy with Catheter Ablation.
Atrial Fibrillation
Catheter Ablation
Heart Failure
Hospitalization
Preserved Ejection Fraction
Prognostic
Journal
Journal of atrial fibrillation
ISSN: 1941-6911
Titre abrégé: J Atr Fibrillation
Pays: United States
ID NLM: 101514767
Informations de publication
Date de publication:
Historique:
received:
05
07
2018
revised:
06
08
2018
accepted:
22
12
2018
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
30
5
2019
Statut:
epublish
Résumé
Atrial fibrillation (AF) and heart failure (HF) often coexist with an increase in morbidity and mortality. AF catheter ablation (CA) has proved to be a safe and efficient option for HF patients, but long-term evolution and prognosis remain uncertain. The aim is to assess the efficacy and safety of CA in HF patients with AF, and analyze HF long-term evolution. We prospectively analyzed consecutive patients with AF and congestive HF or left ventricular ejection fraction (EF) less than 45%, who underwent CA of AF between 2011 and 2016. We excluded patients who did not complete one year of follow-up. Seventy-nine patients were included. Mean age was 62.1 years, 72.4% were men, 67.2% had hypertension and 8.6% were diabetics. Mean EF was 49%, left atrial area was 26.5 cm2 and mean CHA2DS2-VASc score was 2. 70.6% were on NYHA FC II-III.The recurrence rate of AF was 60%, and after a second CA the rate decreased to 27.8%. Only persistent AF prior to the procedure was identified as independent predictor of recurrence. There was a significant NYHA FC improvement in the sinus rhythm (SR) group vs those with recurrence (63.6% vs 36.4%; p=0.047). None of the patients in SR were hospitalized, whereas six with recurrence were hospitalized due to HF (0% vs. 18.2%; p = 0.07). The rate of complications was 9.1%. Catheter ablation of atrial fibrillation in heart failure presents an adequate success rate, improving symptoms and reducing rehospitalizations due to heart failure.
Identifiants
pubmed: 31139301
doi: 10.4022/jafib.2128
pmc: PMC6533823
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2128Références
N Engl J Med. 2002 Dec 5;347(23):1825-33
pubmed: 12466506
N Engl J Med. 2002 Dec 5;347(23):1834-40
pubmed: 12466507
Circulation. 2003 Jun 17;107(23):2920-5
pubmed: 12771006
Lancet. 2003 Sep 6;362(9386):767-71
pubmed: 13678869
Rev Cardiovasc Med. 2003;4 Suppl 7:S21-30
pubmed: 14668697
Cardiovasc Res. 2004 Feb 1;61(2):208-17
pubmed: 14736537
J Cardiovasc Electrophysiol. 2003 Dec;14(12 Suppl):S281-6
pubmed: 15005215
N Engl J Med. 2004 May 20;350(21):2151-8
pubmed: 15152060
N Engl J Med. 2004 Dec 2;351(23):2373-83
pubmed: 15575053
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
JAMA. 2005 Jun 1;293(21):2634-40
pubmed: 15928285
Eur Heart J. 2005 Nov;26(22):2422-34
pubmed: 16204266
N Engl J Med. 2008 Jun 19;358(25):2667-77
pubmed: 18565859
N Engl J Med. 2008 Oct 23;359(17):1778-85
pubmed: 18946063
Eur J Heart Fail. 2009 Jul;11(7):676-83
pubmed: 19553398
JAMA. 2010 Jan 27;303(4):333-40
pubmed: 20103757
J Am Coll Cardiol. 2010 Apr 27;55(17):1796-802
pubmed: 20413028
Heart. 2011 May;97(9):740-7
pubmed: 21051458
N Engl J Med. 2011 Jan 6;364(1):11-21
pubmed: 21073363
J Cardiovasc Electrophysiol. 2012 Oct;23(10):1073-7
pubmed: 22672521
N Engl J Med. 2012 Oct 25;367(17):1587-95
pubmed: 23094720
J Cardiovasc Electrophysiol. 2013 Jan;24(1):24-32
pubmed: 23140485
J Am Coll Cardiol. 2013 May 7;61(18):1894-903
pubmed: 23500267
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):31-8
pubmed: 24382410
JAMA. 2014 Feb 19;311(7):692-700
pubmed: 24549549
Europace. 2014 Aug;16(8):1168-74
pubmed: 24569573
Circulation. 2016 Apr 26;133(17):1637-44
pubmed: 27029350
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358